Lenalidomide

Results: 231



#Item
41Microsoft Word - pomalidomide-psddocx

Microsoft Word - pomalidomide-psddocx

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-04-22 23:39:46
42Medical statistics / Lenalidomide / Multiple myeloma / Bortezomib / Dexamethasone / End point of clinical trials / Thalidomide / Celgene / Clinical trial / Medicine / Health / Immunosuppressants

5.13 POMALIDOMIDE, capsules, 3 mg and 4 mg, Pomalyst®, Celgene Pty Ltd. Purpose of Application

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-04-22 23:39:46
43Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH New Data Suggest a Potential Role for AT9283 in Combination With Lenalidomide and With Docetaxel in the Treatment of Multiple Myeloma and Non-H

Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH New Data Suggest a Potential Role for AT9283 in Combination With Lenalidomide and With Docetaxel in the Treatment of Multiple Myeloma and Non-H

Add to Reading List

Source URL: astx.com

Language: English
44Haematology Clinical Trials The Department of Haematology at Flinders Medical Centre has a Clinical Trials Unit for research into the diagnosis, monitoring, and treatment of haematological disorders. This includes both b

Haematology Clinical Trials The Department of Haematology at Flinders Medical Centre has a Clinical Trials Unit for research into the diagnosis, monitoring, and treatment of haematological disorders. This includes both b

Add to Reading List

Source URL: www.fcic.org.au

Language: English - Date: 2014-02-25 19:14:38
45Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA)

Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA)

Add to Reading List

Source URL: astx.com

Language: English
46National Chemotherapy Algorithms MULTIPLE MYELOMA SEE MYELOMA – TRANSPLANT ELIGIBLE

National Chemotherapy Algorithms MULTIPLE MYELOMA SEE MYELOMA – TRANSPLANT ELIGIBLE

Add to Reading List

Source URL: www.engage.england.nhs.uk

Language: English - Date: 2015-03-23 13:59:26
47Hindawi Publishing Corporation Case Reports in Hematology Volume 2014, Article ID[removed], 7 pages http://dx.doi.org[removed][removed]Case Report

Hindawi Publishing Corporation Case Reports in Hematology Volume 2014, Article ID[removed], 7 pages http://dx.doi.org[removed][removed]Case Report

Add to Reading List

Source URL: downloads.hindawi.com

Language: English - Date: 2014-11-24 07:38:54
48SMC  briefing note Scottish Medicines Consortium advice to NHSScotland

SMC briefing note Scottish Medicines Consortium advice to NHSScotland

Add to Reading List

Source URL: www.scottishmedicines.org.uk

Language: English
49Pharmacology / Immunosuppressants / Orphan drugs / Clinical research / Pharmaceutical Benefits Scheme / Pharmaceuticals policy / Lenalidomide / Multiple myeloma / Bortezomib / Medicine / Chemistry / Health

Drug Name, form(s), strength(s) and Sponsor TGA Indication Current PBS Listing

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-01-19 17:21:09
50Healthcare in Australia / Immunosuppressants / Aging-associated diseases / Piperazines / Pyrimidines / Pharmaceutical Benefits Scheme / Quality use of medicines / Osteoporosis / Lenalidomide / Medicine / Health / Chemistry

The Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) held its 79th meeting on 3–4 October[removed]DUSC is a national focus of excellence in collecting, analysing and interpre

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-03-13 00:20:02